OncoMatch/Blood Cancer — Myeloproliferative (MPN)/JAK2 V617F
Blood Cancer — Myeloproliferative (MPN)JAK2 V617F Clinical Trials
JAK2 V617F is the defining driver mutation in approximately 95% of polycythemia vera (PV) and 50–60% of essential thrombocythemia (ET) and myelofibrosis (MF). Ruxolitinib (JAK1/2 inhibitor) is FDA-approved for PV and MF; fedratinib, pacritinib, and momelotinib provide options in subsequent lines or cytopenic patients. Trials investigate JAK inhibitor combinations with BET, BCL2, MDM2, or PI3K inhibitors and novel JAK2-targeting degraders for myelofibrosis transformation prevention.
Top recruiting JAK2 V617F Blood Cancer — Myeloproliferative (MPN) trials
Ranked by phase and US site count. See all 5 trials matched to your profile →
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
Italfarmaco
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
University of Birmingham
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
University Hospital, Brest
Ruxolitinib in Thrombocythemia and Polycythemia Vera
Massachusetts General Hospital
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Prelude Therapeutics
Browse other molecular targets with active Blood Cancer — Myeloproliferative (MPN) trials.